Finanzen von Lycia Therapeutics, Inc. Common Stock (LYCA)LYCALycia Therapeutics, Inc. Common Stock

In the context of the broader market, LYCA competes directly with industry leaders such as IMCR and TYRA. With a market capitalization of $1.42B, it holds a significant position in the sector. When comparing efficiency, LYCA's gross margin of N/A stands against IMCR's 99.06% and TYRA's N/A. Such benchmarking helps identify whether Lycia Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has a forward P/E of 0 and a price-to-sales ratio of 310.1, indicating it may not be generating revenue relative to its market cap.